Section E – Written questions lodged on 06 May 2015
Questions marked with a triangle (Δ) are initiated by the Scottish Government in order to facilitate the provision of information to the Parliament.
Questions in which a member has indicated a declarable interest are marked with an "R".
S4W-25413 Mary Scanlon: To ask the Scottish Government for how long the Scottish Dental Access Initiative provides financial assistance for dentists to deliver a level of NHS services and what obligation dentists have to provide services thereafter.
S4W-25415 Mary Scanlon: To ask the Scottish Government whether any general dental practitioner has (a) failed to deliver the required level of NHS dental services and (b) repaid financial assistance to an NHS board.
S4W-25416 Mary Scanlon: To ask the Scottish Government what mechanism is in place to ensure that dentists receiving financial assistance to deliver NHS dental services deliver the required level of NHS provision.
S4W-25417 Mary Scanlon: To ask the Scottish Government what role NHS boards have in investigating patient complaints relating to general dental practitioners.
S4W-25418 Mary Scanlon: To ask the Scottish Government whether NHS boards are notified when a dental practice is being investigated following a complaint.
S4W-25434 Richard Simpson: To ask the Scottish Government how much it has cost to treat wet macular degeneration with ranibizumabin in each of the last three years, and what information it has regarding how much it would have cost if bevacizumab had been used.
S4W-25435 Richard Simpson: To ask the Scottish Government what its position is on the reported increase in (a) diagnoses of disorders in young people that require both physical and mental health care and (b) the age range of those accessing paediatric services.
S4W-25436 Richard Simpson: To ask the Scottish Government what its position is on the Cochrane Library review, Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration, which suggests that bevacizumab is an effective and less expensive alternative to ranibizumabin in the treatment of wet macular degeneration and, in light of this, whether it has asked the Scottish Medicines Consortium to consider authorising its use.
S4W-25437 Richard Simpson: To ask the Scottish Government what its position is on introducing legislation to ensure that doctors who act on the basis of the evidence in a Cochrane Library review are protected from legal action.
S4W-25443 Richard Simpson: To ask the Scottish Government how it ensures that paediatric inpatients can access appropriate multidisciplinary mental health care and treatment.
S4W-25445 Mary Scanlon: To ask the Scottish Government what plans it has to review the contract for retained firefighters, and what impact reducing the commitment of them being on call for up to 120 hours each week would have on the numbers taking up the role.
S4W-25446 Liam McArthur: To ask the Scottish Government, further to the answer to question S4W-25348 by Angela Constance on 5 May 2015, whether it has established a timeframe for the Widening Access Commission to report back with its conclusions.
S4W-25448 Siobhan McMahon: To ask the Scottish Government, in light of reports that they are facing possible redundancy, what (a) support and (b) employment protection it will provide to the people covered by the tripartite agreements between it, the Wood Group PSN and Angus College who are yet to complete their apprenticeship.
S4W-25458 Liam McArthur: To ask the Scottish Government, further to the answer to question S4W-25286 by Angela Constance on 6 May 2015, if there is a change in its position, whether it will inform the Parliament before any action is taken.
Back to top